These results show that PI3Kγ inhibitors targeting TAMs may significantly enhance the efficacy of immunotherapy.[38] Targeting macrophage‐derived granulin can be a strategy to improve or restore T‐cell infiltration and cytotoxic function in pancreatic cancer, and as such, this is a potential antitumor therapeutic strategy.[39] Researchers have designed the inhibitor AK750, which not only prevents macrophages from receiving macrophage colony‐stimulating factor (MSF) from cancer cells, but also prevents cancer cells from releasing CD47 protein. The gene discussed is GRN; the disease is familial pancreatic carcinoma.